Deutetrabenazine ( Austedo)

Question 1

What is the generic name of Austedo?

Answer 1

Deutetrabenazine

Question 2

What condition is Austedo primarily indicated for?

Answer 2

Austedo is indicated for the treatment of chorea associated with Huntington’s disease.

Question 3

What is another indication for Austedo besides Huntington’s disease?

Answer 3

Austedo is also indicated for the treatment of tardive dyskinesia.

Question 4

What is the mechanism of action of deutetrabenazine?

Answer 4

Deutetrabenazine works by inhibiting vesicular monoamine transporter 2 (VMAT2), thereby reducing the levels of monoamines in the presynaptic neurons.

Question 5

True or False: Deutetrabenazine is an antipsychotic medication.

Answer 5

False

Question 6

Name one common adverse effect of deutetrabenazine.

Answer 6

Depression

Question 7

Fill in the blank: Deutetrabenazine may cause _______ as a side effect.

Answer 7

somnolence

Question 8

What is a serious adverse effect associated with deutetrabenazine?

Answer 8

Suicidal thoughts or behavior

Question 9

What should be monitored in patients taking deutetrabenazine?

Answer 9

Patients should be monitored for signs of depression and suicidal thoughts.

Question 10

True or False: Deutetrabenazine can be used in patients with hepatic impairment.

Answer 10

False

Question 11

What is the contraindication for using deutetrabenazine?

Answer 11

Deutetrabenazine is contraindicated in patients with a history of suicidal thoughts or behavior.

Question 12

What is the recommended initial dose of deutetrabenazine?

Answer 12

The initial dose is typically 6 mg twice daily.

Question 13

What is the maximum daily dose of deutetrabenazine?

Answer 13

The maximum daily dose is 48 mg.

Question 14

True or False: Deutetrabenazine can interact with MAO inhibitors.

Answer 14

True

Question 15

What type of drug is deutetrabenazine classified as?

Answer 15

Deutetrabenazine is classified as a VMAT2 inhibitor.

Question 16

Fill in the blank: Patients taking deutetrabenazine should avoid _______ medications.

Answer 16

MAO inhibitors

Question 17

What is a key counseling point for patients prescribed deutetrabenazine?

Answer 17

Patients should be advised to report any mood changes or thoughts of self-harm.

Question 18

Name one drug interaction that can occur with deutetrabenazine.

Answer 18

CYP2D6 inhibitors

Question 19

True or False: Deutetrabenazine is safe for use during pregnancy.

Answer 19

False

Question 20

What is the effect of deutetrabenazine on dopamine levels?

Answer 20

Deutetrabenazine decreases dopamine levels in the presynaptic terminals.

Question 21

What should be done if a dose of deutetrabenazine is missed?

Answer 21

Take the missed dose as soon as remembered, but skip if it’s almost time for the next dose.

Question 22

Fill in the blank: Deutetrabenazine is metabolized primarily by the _______ enzyme.

Answer 22

CYP2D6

Question 23

What is a potential consequence of abrupt discontinuation of deutetrabenazine?

Answer 23

Rebound worsening of chorea or dyskinesia.

Question 24

True or False: Deutetrabenazine can cause akathisia.

Answer 24

True

Question 25

What should be done if a patient experiences severe side effects on deutetrabenazine?

Answer 25

Consult a healthcare provider immediately.

Question 26

What is the key safety concern when prescribing deutetrabenazine?

Answer 26

Risk of depression and suicidal ideation.

Question 27

Fill in the blank: Deutetrabenazine is primarily used to manage _______ movements.

Answer 27

abnormal

Question 28

What is the form of administration for deutetrabenazine?

Answer 28

Oral tablet

Question 29

True or False: Deutetrabenazine can cause weight gain.

Answer 29

False

Question 30

What is a recommended monitoring parameter during treatment with deutetrabenazine?

Answer 30

Regular assessment of mental health status.

Question 31

Fill in the blank: Deutetrabenazine should be used with caution in patients with a history of _______.

Answer 31

depression

Question 32

What is the target population for deutetrabenazine therapy?

Answer 32

Adults with Huntington's disease or tardive dyskinesia.

Question 33

What is a unique characteristic of deutetrabenazine compared to other VMAT2 inhibitors?

Answer 33

Deutetrabenazine has a longer half-life due to its deuterated structure.

Question 34

What should patients avoid while taking deutetrabenazine?

Answer 34

Alcohol and other central nervous system depressants.